Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Lipids ; 54(11-12): 707-714, 2019 11.
Artículo en Inglés | MEDLINE | ID: mdl-31574565

RESUMEN

Siphonaxanthin is a carotenoid found in certain green algae, and its promising beneficial properties, such as its anti-obesity effect, have recently been demonstrated. However, there is little information about the molecular mechanisms underlying intestinal absorption of siphonaxanthin. In this study, we aimed to elucidate how siphonaxanthin is transported across the intestinal epithelium using differentiated Caco-2 cells (dCaco-2 cells), recombinant proteins, and an animal model. Siphonaxanthin was taken up by dCaco-2 cells, a model of intestinal epithelial cells, and its uptake linearly increased up to at least 6 h. Pharmacological inhibition of Nieman-Pick C1-like 1 (NPC1L1), but not that of scavenger receptor class B type 1 (SR-B1), significantly suppressed siphonaxanthin uptake by dCaco-2 cells. Results from an in vitro binding assay suggested that the N-terminal domain of NPC1L1, which is an extracellular domain of NPC1L1, binds with siphonaxanthin. Moreover, pretreatment with ezetimibe, an inhibitor of NPC1L1, significantly decreased the plasma level of siphonaxanthin following oral administration in mice. Considered together, we concluded that NPC1L1 promotes siphonaxanthin transport across the intestinal epithelium.


Asunto(s)
Proteínas de Transporte de Membrana/metabolismo , Xantófilas/metabolismo , Administración Oral , Animales , Células CACO-2 , Ezetimiba/administración & dosificación , Ezetimiba/farmacología , Humanos , Absorción Intestinal/efectos de los fármacos , Masculino , Ratones , Ratones Endogámicos ICR , Estructura Molecular , Células Tumorales Cultivadas , Xantófilas/sangre , Xantófilas/química
2.
J Gastroenterol Hepatol ; 34(10): 1751-1757, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31045285

RESUMEN

BACKGROUND AND AIM: A missense variant of the nucleoside diphosphate-linked moiety X-type motif 15 (NUDT15) gene (R139C) predisposes Asian patients with inflammatory bowel disease (IBD) to thiopurine-induced leukopenia. This study evaluates the long-term effect of NUDT15 R139C heterozygosity on hematological parameters during thiopurine administration. METHODS: We enrolled 83 Japanese IBD patients who were on anti-tumor necrosis factor-α agents and had used thiopurine. NUDT15 R139C was genotyped by polymerase chain reaction. We retrospectively reviewed patient clinical charts to collect data on white blood cell (WBC) count, mean corpuscular volume (MCV), hemoglobin, and platelet count during the 24 months following thiopurine initiation. RESULTS: The included patients had either Crohn's disease (54; 65.1%) or ulcerative colitis (29; 34.9%). Genotyping of NUDT15 R139C identified 62 patients (74.7%) of genotype C/C and 21 (25.3%) of genotype C/T. The median dose of thiopurine was lower in the C/T group than in the C/C group after starting thiopurine. At 6 months, the mean WBC count of the C/T group became significantly lower than that of the C/C group (P = 0.008) and remained lower through the 24 months. The C/T group developed grade 2-4 leukopenia by 6 months, which persisted through 12-24 months. The mean MCV in the C/T group became higher than that of the C/C group after 3 months. CONCLUSIONS: NUDT15 R139C heterozygosity affected the WBC count and MCV for 24 months after thiopurine administration. Our results indicate that careful monitoring of leukopenia and dose adjustment are necessary throughout treatment in IBD patients heterozygous for the NUDT15 R139C.


Asunto(s)
Antiinflamatorios/efectos adversos , Azatioprina/efectos adversos , Colitis Ulcerosa/tratamiento farmacológico , Enfermedad de Crohn/tratamiento farmacológico , Fármacos Gastrointestinales/efectos adversos , Leucopenia/inducido químicamente , Leucopenia/genética , Mercaptopurina/efectos adversos , Mutación Missense , Pirofosfatasas/genética , Adulto , Colitis Ulcerosa/diagnóstico , Enfermedad de Crohn/diagnóstico , Índices de Eritrocitos , Femenino , Predisposición Genética a la Enfermedad , Heterocigoto , Humanos , Recuento de Leucocitos , Leucopenia/sangre , Leucopenia/diagnóstico , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo , Factores de Tiempo , Tokio , Resultado del Tratamiento , Adulto Joven
3.
Mol Med Rep ; 4(5): 919-22, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21667028

RESUMEN

The giant jellyfish Nemopilema nomurai (reaching sizes of up to 2 m diameter and 150 kg), which forms dense blooms, has caused extensive damage to fisheries by overloading trawl nets, while its toxic nematocysts cause dermatological symptoms. Giant jellyfish are currently discarded on the grounds of pest control. However, the giant jellyfish is considered to be edible and is part of Chinese cuisine. Therefore, we investigated whether any benefits for human health may be derived from consumption of the jellyfish in order to formulate medicated diets. Antioxidant activity of Nemopilema nomurai was measured using the oxygen radical absorbance capacity (ORAC) and hydroxyl radical averting capacity (HORAC) methods. Based on the results, the ORAC value of the giant jellyfish freeze-dried sample was 541 µmol trolox equivalent (TE)/100 g and the HORAC value was 3,687 µmol gallic acid equivalent (GAE)/100 g. On the other hand, the IC50 value of hydroxyl radical scavenging activity measured by using the electron spin resonance method was 3.3%. In conclusion, the results suggest that the freeze-dried powder of the giant jellyfish Nemopilema nomurai is a potentially beneficial food for humans.


Asunto(s)
Antioxidantes/farmacología , Radical Hidroxilo/metabolismo , Oxígeno/metabolismo , Escifozoos/química , Absorción/efectos de los fármacos , Animales , Depuradores de Radicales Libres/farmacología , Alimentos Funcionales , Humanos , Interacciones Hidrofóbicas e Hidrofílicas , Radical Hidroxilo/química , Concentración 50 Inhibidora
4.
Aust N Z J Public Health ; 35(2): 163-9, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21463414

RESUMEN

OBJECTIVE: To refine and revise previous air pollution, climate and health time series analysis in Christchurch, New Zealand, introducing viral identification data (positive identification count and outbreak, defined as two of more positive tests). METHOD: The effects on daily respiratory admissions for five years (1998-2002) of air pollution (PM(10) ), climate and virology (incorporating actual counts and outbreaks of influenza A and B (INF), para influenza virus type 3 (PIV) and respiratory syncytial virus (RSV) were examined using generalised additive models (GAMs), which are one of semiparametric models. Results were also compared with a model that included climate and air pollution parameters but without the inclusion of virology data. The data were analysed aggregately and then stratified by age group and season. RESULTS: Different virology data detected various association levels. The highest estimates were a 3.93% (CI: 2.69-5.17) and a 3.88% (CI: 2.65-5.12) rise in respiratory admissions for a rise of 10 µg/m(3) annual PM(10) with outbreak and actual counts of PIV respectively for 0-19 years old with a three-day lag. CONCLUSION: Refining a statistical model with the addition of virology data gives a similar estimation of the association between PM(10) levels and respiratory admissions to previous research. Use of the indicator of an outbreak of viral infection appears to be similar to actual count of viruses detected.


Asunto(s)
Contaminantes Atmosféricos/análisis , Contaminación del Aire/efectos adversos , Gripe Humana/epidemiología , Material Particulado/análisis , Admisión del Paciente/estadística & datos numéricos , Infecciones del Sistema Respiratorio/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Contaminación del Aire/estadística & datos numéricos , Niño , Preescolar , Brotes de Enfermedades , Femenino , Humanos , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Modelos Estadísticos , Nueva Zelanda/epidemiología , Análisis de Regresión , Infecciones por Virus Sincitial Respiratorio/epidemiología , Infecciones del Sistema Respiratorio/inducido químicamente , Infecciones del Sistema Respiratorio/virología , Estaciones del Año , Estadísticas no Paramétricas , Factores de Tiempo , Adulto Joven
5.
Ann Nucl Med ; 23(7): 697-9, 2009 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-19557303

RESUMEN

No adverse allergic reactions to iodine-131-metaiodobenzylguanidine ((131)I MIBG) at a diagnostic dose have been reported in the English literature. This report of a skin eruption in a 35-year-old man after an intravenous injection of (131)I MIBG strongly suggests an adverse allergic reaction, and is the first to address such a side effect of (131)I MIBG at a diagnostic dose. Erythematous maculopapular eruptions, some of which were contiguous, were seen in a symmetric disposition on the patient's chest walls, elbows, neck and face 18 h after the (131)I MIBG injection. Antiallergic treatment resolved the lesions completely. There were no possible causes of the exanthema other than the (131)I MIBG injection. Urticaria related to the (131)I MIBG injection and caused by type I allergic reaction was suspected, and these findings point to the possible risk of a hitherto unreported allergic skin reaction to (131)I MIBG. We would like to draw the attention of nuclear physicians to this possible drawback of (131)I MIBG.


Asunto(s)
3-Yodobencilguanidina/efectos adversos , Hipersensibilidad/etiología , 3-Yodobencilguanidina/administración & dosificación , Adulto , Humanos , Masculino , Enfermedades de la Piel/etiología , Enfermedades de la Piel/patología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...